If this is not your name, click here.
| | If this is not your name, click here. | | |
| | Contact Us | Order Now | Journals | Bookstore | Register a colleague | | |
| |  DG DISPATCH - ADA: Troglitazone Successful As Combination Therapy For Diabetics By Cameron Johnston Special to DG News SAN DIEGO, CA -- June 21, 1999 -- Researchers report that troglitazone (Rezulin, Parke-Davis) has a synergistic effect when used as combination therapy with insulin in patients who do not respond to insulin. This combination therapy not only helps patients achieve adequate glycemic control but enables those who are using insulin to reduce their daily dose too, according to the results presented at the American Diabetes Association’s 59th Annual Scientific Sessions in San Diego, CA. The researchers found that combination therapy including either 200 or 400 mg/day of troglitazone was effective in reducing levels of HbA1c and fasting plasma glucose and daily insulin requirements in type 2 diabetics whose glucose was inadequately controlled with insulin alone. These findings were presented by Dr. Lawrence Leiter, director of the lipid disorders clinic at St. Michael’s Hospital, Toronto. Among the 539 patients enrolled in the study, those whose baseline HbA1c was 140 percent above the normal range - indicating that their diabetes was not well-controlled - experienced the greatest benefit, with hemoglobins (HbA1c) levels falling by 1.35 percent from 9.55 to 8.20 percent. HbA1c levels are considered normal at 4 to 6 percent but intervention is only recommended when HbA1c exceeds 7 percent). Fasting plasma glucose declined by 2.5 mmol/l. Those patients whose diabetes was poorly controlled but whose HbA1c was 110 to 140 percent above normal also experienced similar reductions in the markers for insulin response. They achieved a statistically significant reduction in FPG of 1.4 mmol/l and a decline in daily insulin dose of 17.7 units.
|
